ADAM17 and tuberculosis: In 2000, Hernández-Pando and colleagues demonstrated that the administration of batimastat, a broad-spectrum metalloproteinase inhibitor acting on ADAM17, reduces TB control in mice infected with Mtb via intratracheal instillation (Hernandez-Pando et al., 2000).